QCG
AURA icon

Quadrant Capital Group’s Aura Biosciences AURA Stock Holding History

Quadrant Capital Group’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-87
Closed -$538 – 2718
2025
Q3 		$538 Buy
+87
New +$569 ﹤0.01% 2607

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Quadrant Capital Group's AURA Position: Q4 2025 in Review

Quadrant Capital Group sold out of Aura Biosciences (AURA) in Q4 2025, closing a stake of 87 shares — an estimated $538 sold.

Quadrant Capital Group first reported a position in AURA in Q3 2025 and held it in 1 quarter. The position peaked at $538 in Q3 2025. 117 funds tracked by Wall St. Rank hold AURA as of Q4 2025.

  • Quadrant Capital Group reported no remaining Aura Biosciences position as of Q4 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 87 Aura Biosciences shares in Q4 2025, an estimated $538.
  • Quadrant Capital Group first reported a position in Aura Biosciences in Q3 2025 and held it in 1 quarter.
  • Quadrant Capital Group's Aura Biosciences position peaked at $538 in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Aura Biosciences as of Q4 2025.

Based on Quadrant Capital Group's 13F filing for Q4 2025, filed 13 Feb 2026.